Article
Public, Environmental & Occupational Health
Ruxu You, Jinyu Liu, Lei Ke, Guangyi Yu, Yu Zhang, Takahiro Mori
Summary: The study found that sequential teriparatide/zoledronic acid is not cost-effective for Chinese women with postmenopausal osteoporosis, unless the cost of teriparatide is reduced by 50% for participants over the age of 80.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Masashi Uehara, Yukio Nakamura, Takako Suzuki, Masaki Nakano, Jun Takahashi
Summary: This study compared the efficacy and safety of ibandronate and zoledronic acid in Japanese postmenopausal osteoporotic patients, finding that both drugs significantly and safely improved bone turnover markers and BMD during 30 months of treatment. The ZOL group tended to exhibit greater gains in BMD compared to the IBN group, warranting further investigation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Sanchita Agarwal, Stephanie Shiau, Mafo Kamanda-Kosseh, Mariana Bucovsky, Nayoung Kil, Joan M. M. Lappe, Julie Stubby, Robert R. R. Recker, X. Edward Guo, Elizabeth Shane, Adi Cohen
Summary: Premenopausal women with idiopathic osteoporosis (PreMenIOP) have significant deficits in skeletal microstructure. Sequential treatment with teriparatide and denosumab improves bone mineral density and microarchitecture in PreMenIOP. Specifically, after teriparatide treatment, improvements in tibial and radial microarchitecture, density and whole-bone stiffness were observed. After denosumab treatment, increases in volumetric bone mineral density, microstructure and bone strength were seen at both tibia and radius. The findings support the use of sequential treatment with teriparatide followed by denosumab in PreMenIOP.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Medicine, General & Internal
Taewook Kang, Si Young Park, Soon Hyuck Lee, Jong Hoon Park, Seung Woo Suh
Summary: This study compared the effects of DEN and ZOL on postmenopausal women with osteoporosis and found that DEN was associated with greater increase in BMD and TBS, as well as greater inhibition of bone remodeling compared with ZOL.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Endocrinology & Metabolism
Tetsuro Oue, Tomohiro Shimizu, Tsuyoshi Asano, Shun Shimodan, Hotaka Ishizu, Kosuke Arita, Norimasa Iwasaki
Summary: This study aimed to compare the efficacy of switching from romosozumab to denosumab or zoledronic acid in terms of changes in bone mineral density (BMD) and bone metabolism. The results showed that patients who switched to zoledronic acid had higher TRACP-5b levels and lower mean BMD of the lumbar spine compared to other groups after 24 months. The baseline and 12-month TRACP-5b levels were associated with changes in BMD of the lumbar spine after 24 months in patients receiving zoledronic acid, while the baseline TRACP-5b level was associated with changes in BMD in patients receiving denosumab. Therefore, denosumab may be a more effective sequential agent for enhancing BMD after romosozumab, and baseline TRACP-5b levels can predict the efficacy of sequential therapy.
CALCIFIED TISSUE INTERNATIONAL
(2023)
Article
Endocrinology & Metabolism
Tomaz Kocjan, Antonela Sabati Rajic, Andrej Janez, Gaj Vidmar, Nina Orehek, Janja Marc, Barbara Ostanek
Summary: This retrospective study compared bone mineral density changes in postmenopausal women with severe osteoporosis after stopping teriparatide therapy and receiving denosumab or bisphosphonates treatment for 12 months. The results showed that after 12 months, sequential denosumab treatment appeared to yield higher additional lumbar spine bone mineral density gain compared with bisphosphonates treatment.
ENDOCRINE PRACTICE
(2021)
Article
Endocrinology & Metabolism
Giorgia Dito, Marina Lugaresi, Chiara Degradi, Gregorio Guabello, Matteo Longhi, Sabrina Corbetta
Summary: This study compared the efficacy of two different sequential treatment strategies (TPT + ZOL and TPT + Dmab) in severe osteoporotic patients. The results showed that both treatment strategies had similar effects in increasing bone density at the lumbar and hip levels, as well as reducing the risk of fracture.
Article
Pharmacology & Pharmacy
Ruxu You, Jinyu Liu, Lei Ke, Min Wan, Yu Zhang, Guangyi Yu, Takahiro Mori
Summary: This study found that sequential denosumab/zoledronic acid is cost-effective compared to zoledronic acid monotherapy for Chinese postmenopausal osteoporotic women over 70 years old.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Junjun Fan, Tao Liu, Xin Dong, Siguo Sun, Hongtao Zhang, Chunbao Yang, Xin Yin, Bo Liao, Xiaoxiang Li
Summary: This retrospective cohort study found that perioperative treatment with zoledronic acid might provide protection against a significant decrease in bone mineral density of cephalad vertebrae after spinal fusion surgery among postmenopausal women with osteoporosis.
GLOBAL SPINE JOURNAL
(2023)
Article
Endocrinology & Metabolism
H. Hagino, K. Tanaka, S. Silverman, M. McClung, S. R. Gandra, M. Charokopou, K. Adachi, B. Johnson, B. Stollenwerk
Summary: The study assessed the cost effectiveness of romosozumab versus teriparatide for the treatment of severe postmenopausal osteoporosis in Japan. Results showed that romosozumab produced greater health benefits at a lower cost compared to teriparatide.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Kang Wei, Yuxing Qu, Yi Gao, Yong Ma
Summary: This study demonstrated that teriparatide (parathyroid hormone 1-34) in combination with zoledronic acid is more effective than teriparatide alone in treating postmenopausal osteoporosis, with significantly lower pain scores and levels of osteoporosis-related biomarkers, as well as higher bone mineral density values.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Article
Chemistry, Multidisciplinary
Marwa Y. Shaheen, Amani M. Basudan, Abdurahman A. Niazy, Jeroen J. J. P. van den Beucken, John A. Jansen, Hamdan S. Alghamdi
Summary: The study demonstrates that systemic intravenous administration of zoledronate either before or after surgery improves the regeneration of bone defects grafted with inorganic cancellous bovine bone particles in osteoporotic conditions. However, continued pre- and post-surgical zoledronate treatment did not show a favorable effect on bone repair.
APPLIED SCIENCES-BASEL
(2021)
Article
Endocrinology & Metabolism
Emily G. Atkinson, Michele Adaway, Daniel J. Horan, Crystal Korff, Angela Klunk, Ashley L. Orr, Katherine Ratz, Teresita Bellido, Lilian I. Plotkin, Alexander G. Robling, Joseph P. Bidwell
Summary: Activation of bone anabolic pathways is a promising strategy for treating severe osteoporosis. The inactivation of the Nmp4 gene enhances the bone anabolic effects of parathyroid hormone (PTH). The Prx1-expressing mesenchymal stem/progenitor cells (MSPCs) play a crucial role in the efficacy of PTH therapy.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Yumejiro Nakamura, Tomohiro Shimizu, Tsuyoshi Asano, Shun Shimodan, Hotaka Ishizu, Daisuke Takahashi, Masahiko Takahata, Norimasa Iwasaki
Summary: The combination therapy of Zol or DMAb and ELD may increase BMD at 12 months after the first administration in Japanese patients with postmenopausal osteoporosis, regardless of BPs pretreatment. Bone metabolic markers at baseline may be useful predictors for reaction to the therapy and side effects caused by these combination therapies in postmenopausal osteoporosis.
JOURNAL OF BONE AND MINERAL METABOLISM
(2021)
Article
Endocrinology & Metabolism
Nandipati Venkata Sandeep, Aneez Joseph, Kripa Elizabeth Cherian, Nitin Kapoor, Thomas Paul
Summary: This study suggests that teriparatide has a positive effect on bone mineral parameters and bone quality in postmenopausal women in South India.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2022)
Article
Cell Biology
Mikolaj Ogrodnik, Yi Zhu, Larissa G. P. Langhi, Tamar Tchkonia, Patrick Kruger, Edward Fielder, Stella Victorelli, Rifqha A. Ruswhandi, Nino Giorgadze, Tamar Pirtskhalava, Oleg Podgorni, Grigori Enikolopov, Kurt O. Johnson, Ming Xu, Christine Inman, Allyson K. Palmer, Marissa Schafer, Moritz Weigl, Yuji Ikeno, Terry C. Burns, Joao F. Passos, Thomas von Zglinicki, James L. Kirkland, Diana Jurk
Article
Orthopedics
Fabian Plachel, Philipp Heuberer, Renate Gehwolf, Julia Frank, Herbert Tempfer, Christine Lehner, Nadja Weissenbacher, Andrea Wagner, Moritz Weigl, Philipp Moroder, Matthias Hackl, Andreas Traweger
JOURNAL OF ORTHOPAEDIC RESEARCH
(2020)
Article
Endocrinology & Metabolism
Roland Kocijan, Moritz Weigl, Susanna Skalicky, Elisabeth Geiger, James Ferguson, Gabriele Leinfellner, Patrick Heimel, Peter Pietschmann, Johannes Grillari, Heinz Redl, Matthias Hackl
Article
Engineering, Biomedical
Paul Slezak, Andrea Klang, James Ferguson, Xavier Monforte, Peter Schmidt, Barbara Bauder, Angelika Url, Marcin Osuchowski, Heinz Redl, Daniel Spazierer, Heinz Gulle
JOURNAL OF BIOMATERIALS APPLICATIONS
(2020)
Article
Endocrinology & Metabolism
Riikka E. Makitie, Matthias Hackl, Moritz Weigl, Amelie Frischer, Anders Kampe, Alice Costantini, Johannes Grillari, Outi Makitie
JOURNAL OF BONE AND MINERAL RESEARCH
(2020)
Article
Multidisciplinary Sciences
Eleni Priglinger, Karin Strohmeier, Moritz Weigl, Carolin Lindner, Daniela Auer, Mario Gimona, Martin Barsch, Jaroslaw Jacak, Heinz Redl, Johannes Grillari, Matthias Sandhofer, Matthias Hackl, Susanne Wolbank
SCIENTIFIC REPORTS
(2020)
Article
Cell Biology
Victoria Saferding, Melanie Hofmann, Julia S. Brunner, Birgit Niederreiter, Melanie Timmen, Nathaniel Magilnick, Silvia Hayer, Gerwin Heller, Guenter Steiner, Richard Stange, Mark Boldin, Gernot Schabbauer, Moritz Weigl, Matthias Hackl, Johannes Grillari, Josef S. Smolen, Stephan Blueml
Article
Endocrinology & Metabolism
K. Kerschan-Schindl, M. Hackl, E. Boschitsch, U. Foeger-Samwald, O. Naegele, S. Skalicky, M. Weigl, J. Grillari, P. Pietschmann
Summary: This study aimed to investigate and evaluate the diagnostic accuracy of osteomiRs for osteoporosis, revealing their potential application in the prevention and diagnosis of osteoporosis.
CALCIFIED TISSUE INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Kseniya Khamina, Andreas B. Diendorfer, Susanna Skalicky, Moritz Weigl, Marianne Pultar, Teresa L. Krammer, Catharine Aquino Fournier, Amy L. Schofield, Carolin Otto, Aaron Thomas Smith, Nina Buchtele, Christian Schoergenhofer, Bernd Jilma, Bernhard J. H. Frank, Jochen G. Hofstaetter, Regina Grillari, Johannes Grillari, Klemens Ruprecht, Christopher E. Goldring, Hubert Rehrauer, Warren E. Glaab, Matthias Hackl
Summary: The plasma levels of tissue-specific microRNAs can serve as diagnostic, disease severity and prognostic biomarkers. Combining diverse microRNAs into biomarker signatures using multivariate statistics is powerful in terms of tissue and condition specific microRNA shedding into the plasma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Geriatrics & Gerontology
Allancer D. C. Nunes, Moritz Weigl, Augusto Schneider, Sarah Noureddine, Lin Yu, Collin Lahde, Tatiana Dandolini Saccon, Kunal Mitra, Esther Beltran, Johannes Grillari, James L. Kirkland, Tamara Tchkonia, Paul D. Robbins, Michal M. Masternak
Summary: The study reveals that miR-146a-5p expression increases in aging mice but remains youthful in long-living mice. Overexpression of miR-146a-5p exacerbates cellular senescence and inflammation in the visceral adipose tissue of df/df mice, and has similar effects in 3T3-L1 cells under normal glucose conditions.
Article
Orthopedics
Jakob E. Schanda, Philipp Heher, Moritz Weigl, Susanne Drechsler, Barbara Schaedl, Johanna Prueller, Roland Kocijan, Philipp R. Heuberer, Matthias Hackl, Christian Muschitz, Johannes Grillari, Heinz Redl, Xaver Feichtinger, Christian Fialka, Rainer Mittermayr
Summary: This study longitudinally evaluated the effects of zoledronic acid on bone- and muscle-specific miRNAs and investigated muscle tissue regeneration after chronic rotator cuff repair in a rat model. The results showed that zoledronic acid led to significant differences in miRNA levels and improved muscle regeneration after repair.
AMERICAN JOURNAL OF SPORTS MEDICINE
(2022)
Article
Endocrinology & Metabolism
Jens-Jacob Lindegaard Lauterlein, Fatma Gossiel, Moritz Weigl, Richard Eastell, Matthias Hackl, Pernille Hermann, Jens Bollerslev, Morten Frost
Summary: This study investigated the changes in bone phenotype with age in individuals with LRP5-HBM, and compared the quantitative changes in bone turnover markers and miRNAs. The results showed that individuals with LRP5-HBM experience bone loss in the hip region, indicating that the bone phenotype does not uniformly progress with age. The differentially expressed miRNAs may reflect changes in the regulation of bone turnover and balance in LRP5-HBM individuals.